Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes

Pharmacology

Volumn 82, Issue 2, 2008, Pages 156-163

  Fakhoury, Walid ^a   Lockhart, Ian ^a   Kotchie, Robert W ^a   Aagren, Mark ^b   LeReun, Corinne ^c  

^a IQVIA   (United States)

^b NOVO NORDISK A S   (Denmark)

^c NSW Australia   (Australia)

Author keywords

Detemir; Insulin; Neutral protamine Hagedorn; Type 2 diabetes; Weight gain

Indexed keywords

ACARBOSE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN DETEMIR; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EVENING DOSAGE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, ISOPHANE; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; WEIGHT GAIN;

EID: 48449094712     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000149569     Document Type: Article

References (16)

1. Carver C: Insulin treatment and the problem of weight gain in type 2 diabetes. Diabetes Educ 2006;32:910-917.
2. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
3. Jacob AN, Salinas K, Adams-Huet B, Raskin P: Weight gain in type 2 diabetes mellitus. Diabetes Obes Metab 2007;9:386-393.
4. Hermansen K, Davies M: Does insulin detemir have a role in reducing risk of insulin-associated weight gain? Diabetes Obes Metab 2007;9:209-217.
5. Blonde L: State of diabetes care in the United States. Am J Manag Care 2007;13(suppl 2):S36-S40.
6. Cryer PE, Davis SN, Shamoon H: Hypoglycemia in diabetes. Diabetes Care 2003;26:1902-1912.
7. Korytkowski M: When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord 2002;26(suppl 3):S18-S24.
8. Meneghini L: Why and how to use insulin therapy earlier in the management of type 2 diabetes. South Med J 2007;100:164-174.
9. Haak T, Tiengo A, Draeger E, Suntum M, Waldhausl W: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
10. Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P: A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-1274.
11. Philis-Tsimikas A, Charpentier G, Clauson P, Ravn GM, Roberts VL, Thorsteinsson B: Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-1581.
12. Raslova K, Tamer SC, Clauson P, Karl D: Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Investig 2007;27:279-285.
13. Fritsche A, Schweitzer MA, Haring HU; 4001 Study Group: Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-959.
14. Riddle MC, Rosenstock J, Gerich J; Insulin Glargine 4002 Study Investigators: The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.
15. Yki-Jarvinen H, Dressler A, Ziemen M; HOE 901/300s Study Group: Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-1136.
16. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, et al: Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-451.